Samsung Bioepis has announced that the European Medicines Agency (EMA) has accepted for review its market authorization application for SB8, a proposed bevacizumab biosimilar referencing Avastin.
Samsung Bioepis has announced that the European Medicines Agency (EMA) has accepted for review its market authorization application for SB8, a proposed bevacizumab biosimilar referencing Avastin.
The biosimilar was studied in a phase 3 clinical trial in 763 patients with metastatic or recurrent nonsquamous, non—small cell lung cancer (NSCLC). The study, which was completed in October 2018, comprised 2 arms: In each, patients were treated with either the reference Avastin or SB8 in combination with carboplatin and paclitaxel. The primary outcome measure was best objective response rate by week 24. Pharmacokinetics and immunogenicity were also compared between the proposed biosimilar and its reference.
Samsung Bioepis has not yet published the results of the trial.
If the biosimilar is approved, it will join Amgen’s Mvasi and Pfizer’s Zirabev among the ranks of EMA-authorized biosimilar bevacizumab products, and it will be commercialized in Europe by Samsung Bioepis’ partner, MSD (known as Merck in the US and Canadian markets).
The drug is also part of an agreement with 3SBio to commercialize several biosimilars in mainland China; if the drug is approved in the Chinese market, the companies will focus on sales of the biosimilar in the indications of NSCLC and metastatic colon cancer, which have high incidence rates in China.
Among Samsung Bioepis’ other biosimilar assets under development are SB11, a biosimilar ranibizumab referencing Lucentis, which is currently in a phase 3 trial in 705 patients with neovascular age-related macular degeneration, and SB12, a biosimilar eculizumab referencing Soliris, which recently completed a phase 1 clinical trial in 240 healthy volunteers.
The company is also branching out in the development of novel biologics; SB26, a novel ulinastatin-Fc fusion protein that is intended to treat gastrointestinal diseases, is currently in a phase 1 clinical trial in 58 healthy volunteers to explore the safety, tolerability, and pharmacokinetics of the product.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.